Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza virus vaccine, quadrivalent (high-dose)
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Influenza virus vaccine, quadrivalent (high-dose) is an inactivated, split-virion vaccine developed by Sanofi Pasteur for the prevention of influenza in adults aged 65 and older. Marketed as Fluzone High-Dose Quadrivalent and Efluelda, it contains four times the hemagglutinin (HA) antigen content (60 µg per strain, 240 µg total) compared to standard-dose vaccines. This increased antigen load is designed to elicit a more robust immune response in the elderly, who typically experience age-related immunosenescence. The vaccine targets two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata), specifically inducing antibodies against the viral surface glycoproteins hemagglutinin and neuraminidase.
- Brand names
- Fluzone High-Dose QuadrivalentEfluelda
- Other names
- HD-QIVHigh-Dose Quadrivalent Influenza Vaccineinfluenza virus vaccine, quadrivalent (high-dose) (inactivated)
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on influenza virus vaccine, quadrivalent (high-dose).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza virus vaccine, quadrivalent (high-dose).